The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
December 12, 2025
Health Care Law Today
Eleventh Circuit Hears Oral Argument in Landmark Constitutional Challenge to False Claims Act’s Qui Tam Provisions
On December 12, the U.S. Court of Appeals for the Eleventh Circuit heard oral argument in U.S. ex rel. Zafirov v. Florida Medical…
December 11, 2025
Foley Viewpoints
Antitrust Risks and Compliance Strategies in Intellectual Property Portfolio Management
This article analyzes how intellectual property portfolio management can simultaneously promote innovation and present potential…
December 11, 2025
Foley Viewpoints
CARB Releases Proposed Regulations for SB 261 and 253
On December 9, 2025, the California Air Resources Board (CARB) released its proposed regulatory text for the initial regulations…